Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into reports of possible side effects.

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

Key Takeaways U.S. health agencies are investigating possible side effects of a chikungunya vaccineOlder adults, especially ...

The soaring popularity of smartphone apps that scan barcodes on food products to provide health scores are empowering ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) ...